Navigation Links
Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
Date:9/10/2008

PARSIPPANY, N.J., Sept. 10 /PRNewswire/ -- Ferring Pharmaceuticals Inc., a specialty pharmaceutical company, announces the appointment of Paul Korner, M.D., M.B.A. as Vice President, Medical Affairs. Dr. Korner will be responsible for Medical Affairs for Ferring's Infertility, Orthopaedics, Urology, and Gastroenterology therapeutic areas as well as Product Safety.

"As a result of our continued and projected growth, we have expanded and realigned our management staff to best meet our business needs," said Wayne Anderson, President and CEO. "Dr. Korner is exceptionally well qualified to fill this new role, as we continue our quest to achieve rapid new drug approvals by identifying, improving and commercializing late-stage or marketed products in our clinical specialty areas."

Dr. Korner joins Ferring with a broad range of experience in medical affairs, clinical development, management and business development. Prior to joining Ferring, Dr. Korner was Vice President of Medical Affairs, Women's Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the U.S. Women's Healthcare business unit, and managed medical experts supporting Phase II and III development projects. He has also served as Executive Director of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc., and Senior Director of Clinical Research and Development, Women's Health and Bone Repair for Wyeth Research.

Dr. Korner is a board certified obstetrician and gynecologist. He received his M.D. from Loyola University, Stritch School of Medicine near Chicago. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring's line of products includes: EUFLEXXA(R) (hyaluronic acid) for pain from osteoarthritis in the knee; BRAVELLE(R) (urofollitropin for injection, purified); MENOPUR(R) (menotropins for injection, USP); REPRONEX(R) (menotropins for injection, USP); Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert for infertility. Ferring offers the Q-CAP(TM), the first needle-free reconstitution device, for use with its fertility treatments.

Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R) DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology, orthopaedics and infertility. For more information, call 888-337-7464 or visit http://www.FerringUSA.com.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
2. GM Exec Joins Bio-Reaction Industries Board of Directors
3. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
4. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
5. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
6. James C. Powell Joins Nerites Board of Directors
7. Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons
8. Jan Gray Joins Resverlogix Board of Directors
9. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
10. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
11. Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):